Qin Hao serves as a Senior Scientist II in the Pharmacokinetics Sciences Discovery Bioanalytical lab at Novartis Institutes for BioMedical Research (NIBR), where he leverages over 15 years of extensive experience in bioanalytical science. His expertise lies in the development and validation of LC-MS/MS methods,...
Qin Hao serves as a Senior Scientist II in the Pharmacokinetics Sciences Discovery Bioanalytical lab at Novartis Institutes for BioMedical Research (NIBR), where he leverages over 15 years of extensive experience in bioanalytical science. His expertise lies in the development and validation of LC-MS/MS methods, crucial for supporting pharmacokinetics (PK), pharmacokinetics-pharmacodynamics (PKPD), and toxicokinetics (TK) studies during the discovery and preclinical phases of drug development. Qin's role is pivotal in the bioanalysis of in vivo samples, where he quantifies analytes of interest across various disease areas, ensuring that results are presented in a clear and concise manner to facilitate informed decision-making.
At NIBR, Qin has been instrumental in advancing the bioanalytical capabilities for complex therapeutic modalities, including small interfering RNA (siRNA), antisense oligonucleotides (ASO), fatty acid conjugates, and peptides. His in-depth knowledge and hands-on technical expertise in sample preparation and bioanalysis enable him to tackle the unique challenges presented by these innovative drug candidates. Qin's contributions extend beyond routine bioanalysis; he actively engages in assay development and high-throughput screening, employing his skills in drug formulation and DMPK (drug metabolism and pharmacokinetics) to enhance the efficiency of drug discovery processes.
In addition to his technical prowess, Qin is recognized for his collaborative spirit and ability to communicate complex scientific concepts effectively, making him a valuable asset to cross-functional teams. His commitment to advancing biopharmaceutical research aligns seamlessly with NIBR's mission to discover and develop transformative medicines, positioning him as a key player in the future of drug development.
